Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL3439244 | 1.00 | LMNA (0.41) | LMNATHRB | |
| SCHEMBL580181 | 0.92 | — | — | |
| Ammonia Solution, Strong SCHEMBL3761989 | 0.89 | — | — | |
| Ether SCHEMBL9720166 | 0.83 | LMNA (0.50) | LMNATHRB | |
| Ether SCHEMBL9750502 | 0.80 | — | — | |
| 1,1,2,2-Tetrachloroethane SCHEMBL28191474 | 0.76 | TDP1 (0.39) | LMNATHRB | |
| Ether SCHEMBL861634 | 0.76 | — | — | |
| SCHEMBL9117965 | 0.75 | — | — | |
| Ethyl Acetate SCHEMBL4462178 | 0.73 | ALDH1A1 (0.56) | LMNA | |
| Ether SCHEMBL3794585 | 0.73 | ALDH1A1 (0.37) | LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6632954-B2 | Chelate compounds | SOLVIAS AG (CH) | 2003-10-14 | — | — | US | disclosed |
| US-6498256-B2 | CATALYSTS FOR ASYMMETRIC ADDITION REACTIONS, FOR EXAMPLE OF HYDROGEN, TO PROCHIRAL UNSATURATED ORGANIC COMPOUNDS. | SOLVIAS AG (CH) | 2002-12-24 | — | — | US | disclosed |
| US-20020128486-A1 | Phosphinite-oxazolines and metal complexes | PFALTZ ANDREAS (CH) | 2002-09-12 | — | — | US | disclosed |
| US-20020062027-A1 | Phosphinite-oxazolines and metal complexes | SOLVIAS AG (CH) | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020062027-A1 | Phosphinite-oxazolines and metal complexes | OXER1, OXGR1, H1-4 | LMNA 3697/4885THRB 2732/4885 |
| US-20020128486-A1 | Phosphinite-oxazolines and metal complexes | OXER1, OXGR1, H1-4 | LMNA 3697/4885THRB 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.